These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 32833263)

  • 1. Acute myeloid leukemia: 2021 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2020 Nov; 95(11):1368-1398. PubMed ID: 32833263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
    Tang K; Schuh AC; Yee KW
    Curr Oncol Rep; 2021 Aug; 23(10):120. PubMed ID: 34350512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax-based therapies for acute myeloid leukemia.
    Guerra VA; DiNardo C; Konopleva M
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
    Wei AH; Tiong IS
    Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
    Griffiths EA; Carraway HE; Chandhok NS; Prebet T
    Leuk Res; 2020 Apr; 91():106339. PubMed ID: 32146154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
    Richardson DR; Green SD; Foster MC; Zeidner JF
    Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-agent and combination biologics in acute myeloid leukemia.
    Richard-Carpentier G; DiNardo CD
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):548-556. PubMed ID: 31808888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [What is recommended in the treatment of acute myeloid leukemia?].
    Thol F
    Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the overall survival for older adults with AML finally improving?
    Lancet JE
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I treat acute myeloid leukemia in the era of new drugs.
    DiNardo CD; Wei AH
    Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
    Estey E; Karp JE; Emadi A; Othus M; Gale RP
    Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
    Talati C; Sweet K
    Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Treatment Options for Older Patients with Acute Myeloid Leukemia.
    Saxena K; Konopleva M
    Curr Treat Options Oncol; 2021 Mar; 22(5):39. PubMed ID: 33743079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will new agents impact survival in AML?
    Rowe JM
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
    Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
    J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
    Ali S; Dunmore HM; Karres D; Hay JL; Salmonsson T; Gisselbrecht C; Sarac SB; Bjerrum OW; Hovgaard D; Barbachano Y; Nagercoil N; Pignatti F
    Oncologist; 2019 May; 24(5):e171-e179. PubMed ID: 30898889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.